An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Clinical trial NCT02698475 · COMPLETED
Trial details
- NCT number
- NCT02698475
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-01
- Primary completion
- 2017-12-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.